VahatiCor

What VahatiCor does

VahatiCor, Inc. is a private, Santa Clara, California-based medical technology company developing the A-FLUX Reducer System, a catheter-delivered, self-expanding nitinol implant designed to treat Coronary Microvascular Dysfunction (CMD). The hourglass-shaped device is implanted in the coronary sinus to create a controlled narrowing that raises venous back pressure and improves perfusion through the heart's smaller vessels. The company employs proprietary SwiftCell Technology, featuring a tighter mesh weave at the flow-modulation point developed using computational modeling, and offers four size options (9mm, 11mm, 13mm, 15mm) with a repositionable design to match patient anatomy. The A-FLUX Reducer System is an investigational device not yet approved by the FDA and is being evaluated in the SERRA clinical program at six cardiovascular centers in the United States and Europe.

The company operates as a portfolio company of T45 Labs, with Harry Rowland serving as CEO (appointed May 2026 after leading Endotronix to FDA approval and acquisition by Edwards Lifesciences in 2024) and Marwan Berrada-Sounni as Founder and Chairman. VahatiCor's leadership team includes veterans from Boston Scientific, Shockwave Medical, BioVentrix, and Johnson & Johnson, supported by a dedicated Chief Commercial Officer, VP of Regulatory and Quality Affairs, and VP of Clinical Affairs. The company holds FDA Breakthrough Device designation for the A-FLUX system.

VahatiCor's business model centers on eventual hardware sales of the A-FLUX Reducer System to hospitals and cardiovascular centers through direct enterprise sales to interventional cardiology departments. The go-to-market is built around KOL engagement, scientific symposiums at EuroPCR and TCT, peer-reviewed publications, and clinical study expansion. The company is pre-revenue, with a $23 million Series B financing closed in November 2025 (led by S3 Ventures, with Intuitive Ventures and a strategic investor) deployed to advance SERRA-I early feasibility study enrollment, engineering development, and preparation for pivotal trials and regulatory interactions. Pricing details remain undisclosed given the investigational status.

Name

VahatiCor

Legal name

VahatiCor, Inc.

Website

https://vahaticor.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

VahatiCor is a private medtech company developing the A-FLUX Reducer System, an investigational catheter-delivered nitinol implant designed to treat Coronary Microvascular Dysfunction (CMD) in symptomatic patients without obstructive coronary artery disease, with eventual hospital sales targeting interventional cardiology departments in the US and EU.

Ownership category

akta.pro rank

Product category

Interventional Cardiology Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Coronary Stents & Drug-Eluting Technologies (HLAHAFAA)

Keywords

• Coronary microvascular dysfunction
• Interventional cardiology devices
• Coronary sinus implants
• Catheter-based therapy
• Cardiovascular medical devices

Headquarters

HQ city

Santa Clara

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. A-FLUX Reducer System (Medical Device Sales): The company is developing a medical device for the treatment of Coronary Microvascular Dysfunction. Once approved by FDA, the company expects to generate revenue through sales of the A-FLUX Reducer System to hospitals and cardiovascular centers. The device is currently investigational and not approved for commercial use.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

VahatiCor develops the A-FLUX Reducer System, a catheter-delivered, self-expanding nitinol implant placed in the coronary sinus to treat Coronary Microvascular Dysfunction (CMD). The device creates controlled narrowing of the coronary sinus to raise venous back pressure and improve blood flow through the heart's smaller vessels, addressing a condition with no FDA-approved dedicated therapy. The product is investigational and is being evaluated in the SERRA clinical study series at cardiovascular centers in the US and EU.

Product overview

VahatiCor is a medical technology company developing a single lead product—the A-FLUX Reducer System®—a catheter-based interventional implant for treating Coronary Microvascular Dysfunction (CMD). The device uses proprietary SwiftCell® Technology and is currently undergoing clinical evaluation through the SERRA study series (SERRA-I early feasibility study). The company operates as a portfolio company of T45 Labs with headquarters in Santa Clara, California. The A-FLUX Reducer System is the company's sole product and is an investigational device not yet approved for commercial distribution.

Differentiator

Problem solved

Functional benefit

Products and services

• A-FLUX Reducer System A self-expanding nitinol implant delivered by catheter to the coronary sinus, designed to treat Coronary Microvascular Dysfunction (CMD). The hourglass-shaped device uses proprietary SwiftCell Technology with a tighter mesh weave at the narrow point to create controlled narrowing, raising venous back pressure and improving perfusion through the heart's smaller vessels. Available in 9mm, 11mm, 13mm, and 15mm sizes, repositionable up to half deployment. Currently an investigational device not approved for commercial use, evaluated in the SERRA study series at cardiovascular centers in the US and EU.

Quantifiable outcome

• Nine-minute average implantation procedure time in compassionate use cases
• +3 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Yale-New Haven HospitalcoreImplementation/ SI/ Consulting Partner · 17 June 2026First U.S. site to enroll patient in SERRA-I early feasibility study. Dr. Samit Shah, MD, PhD, interventional cardiologist at Yale New Haven Hospital Heart & Vascular Center and assistant professor of medicine at Yale School of Medicine, serves as co-principal investigator.
• T45 LabscoreStrategic or Co-development Partner · 18 November 2025Parent company and portfolio organization. VahatiCor is described as a 'T45 Labs portfolio company.' Marwan Berrada-Sounni serves as President, CEO, and Co-Founder of both T45 Labs and Advanced NanoTherapies, Inc.
• University Medical Center UtrechtcoreImplementation/ SI/ Consulting Partner · 28 October 2024European clinical site for SERRA-I study. Dr. Tim Van de Hoef serves as co-principal investigator for the SERRA-I study. He presented early clinical data at EuroPCR 2025 and 2026.
• Cedars-Sinai Medical CentercoreImplementation/ SI/ Consulting PartnerDr. Bruce Samuels, Interventional Cardiologist at Cedars-Sinai Medical Center, serves on VahatiCor's Board of Directors. Faculty member at EuroPCR 2026.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Shockwave Medical (Johnson & Johnson): Shockwave Medical was acquired by Johnson & Johnson in 2024 and owns Neovasc, whose Reducer is the established coronary sinus implant for refractory angina. This is the most direct comparable to VahatiCor's A-FLUX in mechanism, indication, and clinical setting.
• Neovasc Inc. Neovasc developed the original Reducer coronary sinus narrowing device for refractory angina and is now part of the Shockwave/J&J portfolio. It is the closest pure-play direct competitor to A-FLUX in mechanism and target anatomy, serving the same interventional cardiology cath lab channel.
• Cardiac Dimensions: Cardiac Dimensions develops the Carillon Mitral Contour System, a catheter-delivered implant for functional mitral regurgitation and heart failure. It is comparable as a small-cap, venture-backed interventional implant company addressing heart failure with catheter-based implants in similar anatomy.
• Ancora Heart: Ancora Heart is developing the AccuCinch transcatheter ventricular restoration system for heart failure with reduced ejection fraction. It is comparable to VahatiCor as an early-stage interventional cardiology company pursuing novel heart failure therapies via catheter-based implants.

Broad incumbents

• Edwards Lifesciences: Edwards Lifesciences is a leading structural heart and heart failure device company and acquired Endotronix (VahatiCor CEO Rowland's prior company) in 2024. It represents both a likely strategic acquirer profile for VahatiCor and the broader incumbent competitor set in interventional heart failure.
• Boston Scientific: Boston Scientific is a broad interventional cardiology incumbent with a portfolio including complex coronary intervention, structural heart, and heart failure devices. It employs several of VahatiCor's engineering alumni and represents a likely strategic acquirer for next-generation coronary and heart failure technologies.
• Abbott Vascular: Abbott is a global cardiovascular device leader across coronary intervention, structural heart, and heart failure. It is comparable as a large incumbent whose interventional cardiology sales force could commercialize A-FLUX post-approval and that has historically acquired novel heart failure device assets.

Emerging players

• BioVentrix: BioVentrix is developing catheter-based ventricular restoration technology for ischemic heart failure and is where VahatiCor CTO Kevin Van Bladel previously served as SVP. It is comparable as an emerging interventional heart failure device company in adjacent anatomy and similar clinical development stage.
• Acutus Medical: Acutus Medical is an electrophysiology and interventional cardiac company with catheter-based mapping and ablation technologies. It is comparable as a small-cap, venture-backed interventional cardiology company developing novel catheter-delivered cardiac devices for underserved patient populations.
• JenaValve Technology: JenaValve is a transcatheter aortic valve replacement company focused on aortic regurgitation. It is comparable as an emerging interventional cardiology implant developer pursuing novel transcatheter therapies in structural heart, a category that shares cath lab delivery channels with A-FLUX.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/vahaticor-inc
• Xx.com/VahatiCor

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VahatiCor